PMRA Stock Overview
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.80 |
| 52 Week High | €43.90 |
| 52 Week Low | €26.06 |
| Beta | -0.080 |
| 1 Month Change | -6.29% |
| 3 Month Change | -32.60% |
| 1 Year Change | -33.73% |
| 3 Year Change | -71.00% |
| 5 Year Change | 9.48% |
| Change since IPO | -43.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMRA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -5.1% | -2.0% |
| 1Y | -33.7% | -21.1% | -0.3% |
Return vs Industry: PMRA underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: PMRA underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| PMRA volatility | |
|---|---|
| PMRA Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PMRA's share price has been volatile over the past 3 months.
Volatility Over Time: PMRA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 509 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.
Pharma Mar, S.A. Fundamentals Summary
| PMRA fundamental statistics | |
|---|---|
| Market cap | €467.81m |
| Earnings (TTM) | €1.14m |
| Revenue (TTM) | €158.15m |
411.4x
P/E Ratio3.0x
P/S RatioIs PMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMRA income statement (TTM) | |
|---|---|
| Revenue | €158.15m |
| Cost of Revenue | €9.61m |
| Gross Profit | €148.54m |
| Other Expenses | €147.40m |
| Earnings | €1.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.064 |
| Gross Margin | 93.92% |
| Net Profit Margin | 0.72% |
| Debt/Equity Ratio | 20.6% |
How did PMRA perform over the long term?
See historical performance and comparison